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Abstract
Introduction and hypothesis Urinary tract infections (UTIs)
are considered the most common bacterial infections, espe-
cially in women. The objective of this study was to evaluate
the use of the sublingual bacterial vaccine Uromune® in
order to prevent recurrent UTIs (RUTIs).
Methods This study was conceived as a multicenter observa-
tional study. The clinical history of 319 women who presented
at least 2 episodes ofUTI in the last 6months or 3 in 12months
was reviewed. Data related to treatment and clinical evolution
were recorded and analyzed. A total of 159 patients received
prophylactic treatment with Uromune® for a period of
3 months (group A) and 160 with sulfamethoxazole/trimeth-
oprim 200/40 mg/day for a period of 6 months (group B).
Uromune® contained an inactivated bacterial cell suspension
of selected strains of Escherichia coli,Klebsiella pneumoniae,
Proteus vulgaris, and Enterococcus faecalis.
Results Patients in group A experienced a highly significant
reduction in the number of infections compared to patients
in group B. In the first 3 months, the mean number of
infections was 0.36 versus 1.60 (P<0.0001), respectively.
A significant reduction was also observed after 9 and
15 months (P<0.0001). The numbers of patients who did
not have any UTI at 3, 9, and 15 months were 101, 90, and
55 in group A versus 9, 4, and 0 in group B (P<0.0001).
Conclusions The results obtained in this study favor the use of
this bacterial-based therapeutic vaccine as an effective strategy
to reduce frequency, duration, severity, and costs of RUTIs.
Keywords Recurrent urinary tract infections . Bacterial
vaccine
Introduction
Urinary tract infections (UTIs) are considered the most
common bacterial infections [1, 2], especially in wom-
en. The bladder is the most prevalent site of infection
(cystitis). Some authors stated that women are 30 times
more prone to have UTIs than men [3], while other
authors reported a 8:1 ratio [4]. Because 50–60 % of
women report at least one UTI in their lifetime, UTIs
have become a common condition diagnosed and treated
by urologists, gynecologists, and other health care pro-
viders [1].
At least one fourth of these patients will have a
recurrence within a year [2], and 22 % will have recur-
rent urinary tract infections (RUTIs). Infections are con-
sidered recurrent when patients have three or more
culture-documented infections in a year or two or more in
6 months [5].
The European Association of Urology defines a signifi-
cant bacteriuria as≥103 uropathogens/ml of midstream urine
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in acute uncomplicated cystitis in women, ≥ 104 uropathogens/
ml of midstream urine in acute uncomplicated pyelonephritis in
women, ≥ 105 uropathogens/ml of midstream urine in women,
or≥104 uropathogens/ml of midstream urine in men (or in
straight catheter urine in women) with complicated UTI (in a
suprapubic bladder puncture specimen, any count of bacteria is
relevant) [6].
On average, each episode of acute UTI in premenopausal
women is associated with 6.1 days of symptoms, 2.4 days of
school or work absenteeism, and 0.4 days in bed [1].
Besides the clinical impact on the health and quality of
life, RUTIs have a great economic impact. An annual
cost of US$2.5 billion is estimated in the USA [5].
Bacteriuria is found in 2–3 % of women 15–24 years
of age, 20 % in women 65–80 years of age, and 25–50 % in
women greater than 80 years of age [7]. The population of
women greater than 65 years of age in the USA is
projected to double between 2000 and 2030 [8]. There-
fore, it could be anticipated that UTIs will increase in
the upcoming years. Aside from being common in the
community, 2 % of the hospitalized patients acquire
UTIs. In the 1980s, nosocomial infections accounted
for more than 500,000 per year [9, 10].
Continuous prophylaxis with antibiotics is the recom-
mended initial therapy for RUTIs. Sulfamethoxazole/tri-
methoprim (SMX/TMP) for a period of 6 months is the
most commonly recommended option [11]. However, the
continuous use of antibiotics is not free of risk. Multiresist-
ance of the bacteria to antibiotics is widely increasing,
which creates the dramatic situation that more than 40 %
of the bacterial strains are resistant to available antibiotics in
some regions of the world. An added problem is the high
incidence of adverse reactions associated with the use of
antibiotics and other chemotherapeutics.
Therefore, it is reasonable to consider other preventive
strategies such as those that reinforce the natural mecha-
nisms of pathogen defense.
The objective of this study was to evaluate clinical
benefit obtained with the prophylactic use of a bacterial-
based sublingual vaccine (Uromune®) compared with




This study was conceived as a multicenter retrospective
observational study. It was approved by the Ethics Committee
of the University Hospital of Salamanca (Spain) and was
accepted by the Spanish Health Authorities (Agencia Espa-
ñola del Medicamento).
Patient population
The sample size of the number of clinical histories to review
was calculated based on the data of Palou et al. [12] describing
that more than 11.8 of the population have more than 2 UTIs.
Expecting to have a 65% reduction in the number of UTIs, for
an α00.05 and a power of 80 % (error protection of 7.84)
[13], the number of clinical histories to review was a mini-
mum of 314.
Finally, the clinical history of 319 women who presented
with at least 2 episodes of UTI in the last 6 months or 3 in
the last 12 months was reviewed. Data related to medical
and surgical background, gynecological/obstetric records,
sexual habits, usual treatment, specific treatment, and evo-
lution were recorded and analyzed. Between groups there
were no clinically relevant differences regarding age, hor-
monal status, coital activity, or usual treatment. The ethnic
group and the dietetic habits were the same in all patients.
Epidemiological data on age, months of evolution of RUTI,
and the mean number of UTIs and positive urocultures (UC+)
in a period of 6 months are shown in Table 1. Once the clinical
histories were reviewed, 159 patients were treated with Uro-
mune® (group A) and 160 with SMX/TMP (group B). In this
review, we found that the clinical history of the patients who
suffered an UTI had the corresponding UC and were treated
with different antibiotics (ciprofloxacin, cefuroxime, amoxi-
cillin/clavulanic acid, etc.).
Treatments
Uromune® is a commercially available bacterial vaccine
produced (in Spain as a named patient preparation) by
Inmunotek (Madrid, Spain) and marketed by Q-Pharma
(Alicante, Spain). The vaccine consisted of two vials con-
taining a suspension of 109 inactivated whole bacteria/ml.
The vaccine is a mixture of equal amounts of selected strains
of Escherichia coli, Klebsiella pneumoniae, Proteus vulga-
ris, and Enterococcus faecalis. These microorganisms are
considered to produce the majority of RUTIs in Spain [14].
The delivery route was through the sublingual mucosa and
the dose was 2 puffs of 100 μl each (108 bacteria/puff) daily
avoiding the concomitant intake of food or beverage. The
delivered dose was maintained under the tongue for a period
of 1–2 min and then swallowed. The patients in group A
received this treatment during a period of 3 months.
SMX/TMP (200/40 mg/day) was administered orally to
patients in group B as a prophylactic treatment for a period
of 6 months [11, 15, 16].
The clinical history of all patients contained the data
concerning each episode of UTI. Furthermore, group A
had a routine control after completion of the 3-month
treatment with Uromune® and group B after 6 months
of SMX/TMP.
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Evaluation
The following data were collected before the initiation of the
corresponding treatment and after 3, 9, and 15 months: (1)
number of UTIs, (2) time of evolution of RUTIs before
initiation of treatment, and (3) number of UC+.
Statistics
The Excel spreadsheet (Microsoft Corp., Redmond, WA,
USA) and the statistical software SPSS v.11.0 (SPSS Inc.,
Chicago, IL, USA) were used. Descriptive statistics of the
number of UTIs and UC+ were expressed as the mean in the
corresponding period with 95 % confidence intervals (CI).
Student’s t test was used to compare the number of UTIs and
UC+ between both groups before the initiation of treatment
and 3, 9, and 15 months of evolution. Repeated measures
analysis of variance (ANOVA) was used to evaluate the
evolution of the number of UTIs and UC+ of each group
at 3, 9, and 15 months of observation. Fisher’s exact test was
used to compare between both groups the number of
patients who did not experience any UTIs or UC+ after 3,
9, and 15 months.
The relationship between the mean number or UTIs or
UC+ and the time of observation (3, 9, and 15 months) was
estimated by the regression line analysis Y 0 a + bX, in
which Y is the number of UTIs or UC+ and X the time
(months of evolution). For testing the regression lines for
parallelism (i.e., equality of slopes) the t test was used [17].
Results
Clinical profile
Both groups of patients were similar in terms of age, time of
evolution of UTIs, and the mean number of UTIs and UC+
for a period of 6 months (Table 1) before the initiation of the
Table 1 Demographic data of
the patients evaluated
aMean number of episodes in a
6-month period
Group A Group B P
Age 47.7 (45.0–50.4) 48.1 (45.1–51.0) 0.8536
Age range 16-85 16-87
Time of evolution (months) 56.7 (44.7–68.7) 59.2 (47.8–70.6) 0.7641
Mean number of UTI/6 monthsa 3.2 (2.7–3.7) 3.1 (2.8–3.3) 0.2789
Mean number of UC+/6 monthsa 2.4 (2.0–2.8) 2.2 (2.0–2.4) 0.6392
Table 2 Distribution of the
clinical variables in women with
repeated UTI
aAge assessed with Student’s t
test and other variables with
Fisher’s exact test
Group A Group B Pa
Age (range) 47.7 (45.0-50.4) 48.1 (45.1-51.0) 0.8525
Regular sexual activity 130 122 0.2716
Menopause 64 75 0.2594
Eutocic childbirth 90 87 0.7358
Dystocic childbirth 28 33 0.5694
Multiparous 61 72 0.2566
Nulliparous 41 40 0.8982
Drug allergy 32 29 0.6716
Arterial hypertension 41 52 0.2181
Diabetes mellitus 24 29 0.5478
Smoking habit 43 50 0.4602
Obesity 30 45 0.0642
Cystocele > grade 2 0 0 1.0000
Antidepressant/anxiolytic drugs 58 61 0.8171
Breathing disorders 22 29 0.3596
Stomach disorders 39 45 0.5254
Hysterectomy 50 56 0.5527
Double oophorectomy 42 49 0.4573
Surgical correction of urinary incontinence 38 31 0.3439
Surgical correction of cystocele 18 15 0.5868
Caucasian race 150 149 0.8180
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treatments. They were also similar in terms of sexual activ-
ity, menopause status, records of eutocic or dystocic child-
birth, multiparous or nulliparous status, allergies, arterial
hypertension, type 1 and 2 diabetes, smoking habit, obesity
(body mass index >30), cystocele>grade 2, treatment for
depression, breathing or stomach disorders, surgical back-
ground including hysterectomy, double oophorectomy, surgery
for urinary incontinence (Marshall-Marchetti-Krantz colposus-
pension, tension-free vaginal tape, or transobturator vaginal
tape), pelvic organ prolapse repair, or race (Table 2).
Safety
Regarding Uromune®, none of the patients reported any side
effects, either local at the site of administration or systemic.
Urinary tract infections
The group treated with Uromune® experienced a highly
significant reduction in the number of infections compared
to group B. In the first 3 months the mean number of
infections was 0.36 and 1.60 (P<0.0001), respectively. A
highly significant reduction was also observed after 9 and
15 months (P<0.0001) (Table 3, Fig. 1). The improvement
of the patients in group A compared to group B was 75 % in
the first 3 months and 86 and 77 % at 9 and 15 months,
respectively. The statistical analysis of the evolution of the
number of UTIs in both groups was significant (ANOVA, P<
0.001). The numbers of patients who did not suffer any UTI at
3, 9, and 15 months were 101, 90, and 55 in group A, whereas
in group B there were 9, 4, and 0 (P<0.0001) (Table 4).
Table 3 Mean number of UTIs and UC+ (with 95 % CI) between the
different evaluation time points in the clinical history of the patients
Group A Group B P
UTIs
0–3 months 0.36 (0.29–0.44) 1.60 (1.49–1.71) <0.0001
0–9 months 0.72 (0.60–0.85) 3.71 (3.43–3.99) <0.0001
0–15 months 1.35 (1.15–1.54) 5.75 (5.37–6.13) <0.0001
3–9 months 0.36 (0.24–0.47) 2.11 (1.89–2.34) <0.0001
3–15 months 0.98 (0.79–1.17) 4.15 (3.83–4.47) <0.0001
9–15 months 0.62 (0.48–0.77) 2.04 (1.85–2.23) <0.0001
UC+
0–3 months 0.50 (0.42–0.57) 3.18 (0.08–6.28) <0.0001
0–9 months 1.06 (0.91–1.22) 9.95 (0.26–19.64) <0.0001
0–15 months 1.34 (1.15–1.53) 15.18 (0.39–29.97) <0.0001
3–9 months 0.57 (0.43–0.71) 3.41 (3.16–3.65) <0.0001
3–15 months 0.84 (0.67–1.02) 6.04 (5.71–6.36) <0.0001
9–15 months 0.77 (0.64–0.91) 2.63 (2.43–2.83) <0.0001
Fig. 1 Average of UTIs at the 3-, 9-, and 15-month evaluation time
points. Error bars are±1 standard deviation
Table 4 Number of patients free of UTIs and UC+ between the
different evaluation time points in the clinical history of the patients
Group A Group B P
UTIs
0–3 months 101 9 <0.0001
0–9 months 77 4 <0.0001
0–15 months 55 0 <0.0001
3–9 months 126 32 <0.0001
3–15 months 90 6 <0.0001
9–15 months 108 23 <0.0001
UC+
0–3 months 80 5 <0.0001
0–9 months 56 0 <0.0001
0–15 months 49 0 <0.0001
3–9 months 111 3 <0.0001
3–15 months 95 1 <0.0001
9–15 months 70 6 <0.0001
Fig. 2 Average of UC+ at the 3-, 9-, and 15-month evaluation time
points. Error bars are ± 1 standard deviation
130 Int Urogynecol J (2013) 24:127–134
Urocultures
In the 3 months previous to the initiation of treatment, the
total number of UC+ in both groups was 902 (422 in group
A and 480 in group B). Once the prophylactic treatment was
initiated, group A patients had significantly less UC+ than
group B. The mean of UC+ at 3, 9, and 15 months was 0.50,
1.06, and 1.34 in group A versus 1.60, 5.01, and 7.64 in
group B. The differences between both groups at each
evaluation time point were highly significant (P<0.0001)
(Table 3, Fig. 2). The statistical analysis of the evolution of
the number of UC+ (ANOVA) was significant (P<0.001) in
both groups. The numbers of patients who did not have any
UC+ at 3, 9, and 15 months were 80, 56, and 49 in group A,
whereas in group B there were 5, 0, and 0 (P<0.0001)
(Table 4). The bacteria isolated in the urocultures are shown
in Table 5.
Regression analysis
Table 6 and Fig. 3 show the parameters of the regression
analysis between the mean number or UTIs or UC+ and the
time of observation (slope, intercept, correlation coefficient,
standard error of the slope, and the t test for parallelism).
The regression lines were not parallel, since the slope of
evolution of UTIs in group B was 4.23 times bigger than the
slope of group A. In the case of UC+, the slope was 7.16
times bigger.
Discussion
In this retrospective observational study we collected the
data from the clinical histories of the clinical evolution of
319 women affected by RUTIs, comparing the clinical im-
pact of the prophylactic treatment with a bacterial vaccine
(Uromune®) and the currently accepted antibiotic therapy.
We established the composition of this named patient bac-
terial preparation, for the prophylactic treatment of our
patients, on the basis of the most common bacteria causing
urinary infections in Spain [14]. Group A patients were
treated with Uromune® for a period of 3 months without











































































































































































































































































































































































































































































































































































































































0 Table 6 Parameters of the regression lines corresponding to the evo-
lution in the number of UTIs and UC+ along the time of evaluation
a b r2 Sb t P
UTI A 0.075 0.082 0.999 0.012 6.789 0.021
B 0.575 0.346 0.976 0.037
UC+ A 0.334 0.070 0.994 0.014 12.345 0.007
B 0.437 1.000 0.962 0.074
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75 % in the number of UTIs when compared to the number
of UTIs of group B in the same period of time, although this
group was under prophylactic antibiotic treatment for a
period of 6 months. The benefit of Uromune® was main-
tained after an observation period of 9 and 15 months
(86 and 77 % of improvement, respectively).
Bacterial preparations have been used to prevent RUTIs.
Lettgen [18] reported the use of an oral bacterial lysate of
109 E. coli compared with the use of nitrofurantoin as a
prophylaxis of RUTIs in girls, showing that the efficacy of
the long-term administration of this bacterial lysate was
comparable to that of nitrofurantoin. Bauer et al. [19]
reported in 2002 a meta-analysis performed on five studies
of an oral bacterial lysate of 109 E. coli compared to placebo
in double-blind studies in patients with UTI (601 women),
showing superiority of this treatment over placebo, with a
confidence interval of 0.64-0.72. The drug was well tolerated
and patient compliance was excellent in all studies. The same
authors reported in 2005 [20] a double-blind, placebo-
controlled study in 454 women using the same product.
Patients were treated with 1 capsule (active or placebo) per
day for 90 days, 3 months without treatment, then the first
10 days in months 7, 8, and 9 and were followed up during
12 months. The authors reported a 34 % reduction of UTIs in
patients treated with the bacterial lysate when compared to
placebo. In our study, patients were treated for a period of
3 months and showed a reduction of 75, 86, and 77 %
at 3, 9, and 15 months when compared with conven-
tional antibiotic prophylaxis, not to placebo. This high
difference in the clinical benefit could be explained by
the form in which the antigen is delivered (lysate or
whole inactivated bacteria) and the route of administra-
tion (orally swallowed or sublingual).
Purified components from bacteria selectively activate
Toll-like receptors (TLR), leading to shared and unique
responses in innate immune cells, whereas whole non-
lysate bacteria contain agonists for multiple TLR and induce
a common macrophage activation program [21] eliciting a
more potent and robust response [22], because the innate
immune response to whole bacteria is a consequence of the
cumulative activation of TLR [23].
These products act through the mucosal immune system.
This local system contributes almost 80 % of all immunocytes.
These cells are accumulated in, or in transit between, various
mucosa-associated lymphoid tissues (MALT), which together
form the largest mammalian lymphoid organ system [24] and
are considered as the “common mucosal immune system”
whereby immunocytes activated at one site disseminate immu-
nity to remote mucosal tissues, although there is a significant
degree of compartmentalization linking specific mucosal in-
ductive sites with particular effector sites [24]. Oral immuniza-
tion (swallowed) may induce substantial immune responses in
the small intestine (strongest in the proximal segment),
ascending colon, and mammary and salivary glands, but
it is relatively inefficient at evoking response in the
distal segments of the large intestines, tonsils, or female
genital tract mucosa [25–27]. However, sublingual and
nasal mucosa can serve as an inductive site for gener-
ating a broad spectrum of mucosal and systemic immune
responses, including also the respiratory and genitourinary
tracts [24, 28] with a high degree of efficacy and persistence
of the immune response [29]. Sublingual administration of
immunogens such as cholera toxin and ovalbumin indu-
ces systemic humoral dose-dependent immune responses
[28], mucosal antibody responses [28], and an immune-
stimulating effect on CD4+ T helper cell responses to
bacteria [30].
The number of UTIs increases after the 3 months of
treatment with Uromune®, being more pronounced from
the 9th month of observation. This observation highlights
the need for a more prolonged treatment or for starting a
new period of 3-month treatment. In a pilot trial using a
similar immunostimulant, with a different bacterial compo-
sition because it focused on preventing recurrent respiratory
tract infections, the treatment period was of 6 months’ du-
ration and had a clinical effect for a minimum period of
12 months [30].
An important finding, not described previously, is the
trend of developing UTIs and the presence of UC+ by
means of the regression analysis. The corresponding slopes
in group A are much flatter than those of group B,
indicating that the trend to develop UTIs and to have
UC+ is much more meaningful in group B and showing
that for one UTI in group A there are more than four
UTIs in group B and for one UC+ in group A there are
more than seven in group B.
Fig. 3 Regression lines of the
evolution in the number of
UTIs and UC+ along the time
of evaluation
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The decrease in the number of UTIs implies an important
decrease in antibiotic consumption. This approach is in line
with the recommendations of health authorities, because the
use of this immunostimulant agrees with the need for new
treatment alternatives, non-antimicrobial treatments (vac-
cines) against bacterial diseases and diseases that may pre-
cipitate secondary bacterial diseases [31–35].
This study demonstrates the effectiveness of a bacterial
preparation administered through the sublingual route. We
acknowledge that because this study is retrospective, it does
not provide deeper and more accurate outcomes as could be
obtained in a prospective explanatory double-blind placebo-
controlled trial conducted under clinical experimental con-
ditions. However, the data collected from clinical histories
of patients provide clinically valuable information of the
patients treated under “real-life” conditions.
However, we believe that further prospective double-
blind, placebo-controlled, randomized clinical trials are
needed to establish more accurately the clinical impact
(severity of episodes of UTI, quality of life, associated
economic costs) of these bacterial immune stimulants in
patients with RUTIs, although the Note of Clarification on
Paragraph 29 added by the World Medical Association
General Assembly to the Declaration of Helsinki [36] states
that care must be taken in using a placebo-controlled trial
and that this methodology should only be used in the ab-
sence of an existing proven therapy.
Considering the clinical impact due to the high preva-
lence and the high cumulative cost of UTIs, together with
the increasing resistance to antibiotics, the results obtained
in this study favor the use of bacterial immunostimulation,
which could be an effective strategy to reduce frequency,
duration, severity, and costs of RUTIs in adults and children.
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